A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2.

Abstract	Maturity-onset diabetes of the young (MODY) is a group of disorders accounting for 2-5% of diabetes; MODY2 is caused by inactivating GCK mutations. We report a case of MODY2 caused by a novel GCK mutation and demonstrate differential glycemic/C-peptide responses to treatment with insulin, no medication, and an oral sulfonylurea.
Authors	Lindsey A Loomba-Albrecht, Maryam Jame, Andrew A Bremer
Journal	Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 87 Issue 3 Pg. e23-5 (Mar 2010) ISSN: 1872-8227 [Electronic] Ireland
PMID	20015564 (Publication Type: Case Reports, Journal Article)
Chemical References	Blood Glucose C-Peptide Hypoglycemic Agents Sulfonylurea Compounds glimepiride Glucokinase
Topics	Adolescent Area Under Curve Blood Glucose (genetics, metabolism) C-Peptide (blood, genetics) Child, Preschool Diabetes Mellitus, Type 2 (drug therapy, genetics) Genetic Predisposition to Disease Glucokinase (genetics) Glucose Tolerance Test Humans Hypoglycemic Agents (therapeutic use) Male Mutation Sulfonylurea Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!